Subscribe to RSS
DOI: 10.1055/s-0028-1088152
The First Convenient Entry to δ-Formyl-δ-valerolactone Precursor for the Synthesis of Statins via Lactonized Side Chain
Publication History
Publication Date:
20 March 2009 (online)
![](https://www.thieme-connect.de/media/synlett/200907/lookinside/thumbnails/10.1055-s-0028-1088152-1.jpg)
Abstract
(4R,6S)-4-(tert-Butyldimethylsilyloxy)-6-formyltetra-hydro-2H-pyran-2-one has been prepared for the first time by oxidation of alcohol (4R,6S)-4-(tert-butyldimethylsilyloxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-2-one. The oxidation of the alcohol was performed with Dess-Martin periodinane in up to 95% yield. Because of limited stability of the aldehyde, it was isolated in the form of hydrate for isolation and storage purposes. The latter can be dehydrated back to the aldehyde quantitatively by simple dissolution in an apolar organic solvent followed by removal of volatiles. The aldehyde was demonstrated to undergo Wittig olefination in high yield. Presented findings set a key platform for statin synthesis via lactonized side chain.
Key words
lactones - aldehydes - oxidations - drugs - statins
-
1a
Endo A.Hasumi K. Nat. Prod. Rep. 1993, 10: 541 -
1b
Tobert JA. Nat. Rev. Drug Discovery 2003, 2: 517 -
1c
Lahera V.Goicoechea M.de Vinuesa SG.Miana M.de las Heras N.Cachofeiro V.Luno J. Curr. Med. Chem. 2007, 14: 243 - 2
Istvan ES.Deisenhofer J. Science 2001, 292: 1160 - 3
Endo A.Kuroda M.Tsujita Y. J. Antibiot. 1976, 29: 1346 - Also known as mevinolin, with a brand name of Mevacor® (Merck & Co). For selected literature, see:
-
4a
Endo A. J. Antibiot. 1979, 32: 852 -
4b
Alberts AW.Chen J.Kuron G.Hunt V.Huff J.Hoffman C.Rothrock J.Lopez M.Joshua H.Harris E.Patchett A.Monaghan R.Currie S.Stapley E.Albers-Schonberg G.Hensens O.Hirshfield J.Hoogsteen K.Liesch J.Springer J. Proc. Natl. Acad. Sci. U.S.A. 1980, 77: 3957 - 5 FDA approved in 1996, also known
as eptastatin with a brand name of Pravachol® (Bristol-Myers
Squibb). See:
Tsujita Y.Kuroda M.Shimada Y.Tanzawa K.Arai M.Kaneko I.Tanaka M.Masuda H.Tarumi C.Watanabe Y. Biochim. Biophys. Acta 1986, 877: 50 - 6 Also known as velostatin, with a
brand name of Zocor® (Merck & Co).
For selected literature, see:
Hoffman WF.Alberts AW.Anderson PS.Chen JS.Smith RL.Willard AK. J. Med. Chem. 1986, 29: 849 - 7 FDA approved in 1996, with a brand
name of Lipitor® [Pfizer (Parke-Davis)].
For selected literature, see:
Roth BD.Blankley CJ.Chucholowski AW.Ferguson E.Hoefle ML.Ortwine DF.Newton RS.Sekerke CS.Sliskovic DR.Stratton CD.Wilson M. J. Med. Chem. 1991, 34: 357 - 8 FDA approved in 2003, with a brand
name of Crestor® (AstraZeneca). For selected
literature, see:
Watanabe M.Koike H.Ishiba T.Okada T.Sea S.Hirai K. Bioorg. Med. Chem. 1997, 5: 437 - 9 FDA approved in 1993, with a brand
name of Lescol® (Novartis Pharma AG). For selected
literature, see:
Fuenfschilling PC.Pascale H.Mutz J.-P. Org. Process Res. Dev. 2007, 11: 13 ; and references cited therein - 10 For selected literature, see:
Suzuki M.Iwasaki H.Fujikawa Y.Kitahara M.Sakashita M.Sakoda R. Bioorg. Med. Chem. 2001, 9: 2727 - 11
Sit SY.Parker RA.Motoc I.Han W.Balasubramanian N.Catt JD.Brown PJ.Harte WE.Thompson MD.Wright JJ. J. Med. Chem. 1990, 33: 2982 -
12a
Choi H.Shin H. Synlett 2008, 1523 -
12b
Rádl S. Synth. Commun. 2003, 33: 2275 -
12c
Bode SE.Wolberg M.Müller M. Synthesis 2006, 557 ; and references therein - 13
Cardani S.Scolastico C.Villa R. Tetrahedron 1990, 46: 7283 - 14
Beck G.Kesseler K.Baader E.Bartmann W.Bergmann A.Granzer E.Jendralla H.Von Kerekjarto B.Krause R.Paulus E.Schubert W.Wess G. J. Med. Chem. 1990, 33: 52 - 15
Časar Z. Synlett 2008, 2036 - 16
Greenberg W.Varvak A.Hanson SR.Wong K.Huang H.Chen P.Burk MJ. Proc. Natl. Acad. Sci. U.S.A. 2004, 101: 5788 -
17a
Rosen T.Taschner MJ.Heathcock CH. J. Org. Chem. 1984, 49: 3994 -
17b
Tang J.Brackenridge I.Roberts SM.Beecher J.Willetts AJ. Tetrahedron 1995, 51: 13217 -
17c
Ghorpade SR.Kalkote UR.Chavan SP.Bhide SR.Ravindranathan T.Puranik VG. J. Org. Chem. 2001, 66: 6803 - 18
Tararov VI.Andrushko N.Andrushko V.König G.Spannenberg A.Börner A. Eur. J. Org. Chem. 2006, 5543 - 19
Gillard F.Heissler D.Riehl J.-J. J. Chem. Soc., Perkin Trans. 1 1988, 2291 - For example, see:
-
20a
Coutrot P.Grison C.Bomont C. J. Organomet. Chem. 1999, 586: 208 -
20b
Corey EJ.Pyne SG.Su W. Tetrahedron Lett. 1983, 24: 4883 -
21a
Dess DB.Martin JC. J. Org. Chem. 1983, 48: 4155 -
21b For recent review on hypervalent
iodine reagents for the oxidation of alcohols, see:
Tohma H.Kita Y. Adv. Synth. Catal. 2004, 346: 111 - 23
Kralj B.igon D.Košmrlj J.Polanc S. Rapid Commun. Mass Spectrom. 1997, 11: 335 -
24a
Wu J.Serianni AS. Carbohydr. Res. 1991, 210: 51 -
24b
McAlpine JM.Riggs NV. Aust. J. Chem. 1975, 28: 211 - 28
Sabitha G.Sudhakar K.Srinivas C.Yadav JS. Synthesis 2007, 705
References and Notes
Synthesis of (4 R ,6 S )-4-( tert -Butyldimethylsilyloxy)-6-(dihydroxymethyl)tetrahydro-2 H -pyran-2-one (4) A mixture of 2 ¹5 (500 mg, 1.92 mmol) and DMP (896 mg, 2.11 mmol) in CH2Cl2 (50 mL) was stirred at 26 ˚C for 30 min. The mixture was diluted with MTBE (35 mL) and washed with sat. NaHCO3 (45 mL). The organic phase was separated. The water phase was additionally extracted with MTBE (3 × 25 mL). Combined organic layers were washed with sat. aq Na2S2O3 (2 × 25 mL), sat. NaHCO3 (2 × 25 mL), H2O (70 mL), dried (MgSO4), and concentrated under reduced pressure to give pure hydrate 4 (498 mg, 94%) as a white crystalline powder; mp 73-75 ˚C. ¹H NMR (300 MHz, THF-d 8): δ = 0.10 (s, 6 H, CH3Si), 0.91 (s, 9 H, CH3C), 1.80-2.00 (m, 2 H, H-5), 2.39 (dd, J = 17.1, 3.9 Hz, 1 H, H-3), 2.58 (dd, J = 17.1, 4.2 Hz, 1 H, H-3), 4.35-4.45 (m, 2 H, H-4, H-6), 4.83-4.91 [m, 1 H, CH(OH)], 5.14 (d, J = 6.0 Hz, 1 H, OH), 5.22 (d, J = 6.0 Hz, 1 H, OH). ¹³C NMR (75 MHz, THF-d 8): δ = -4.79 (CH3Si), -4.74 (CH3Si), 18.7 (CCH3), 26.2 (CH3C), 31.0 (C-5), 40.4 (C-3), 65.1 (C-4), 79.1 (C-6), 91.7 [CH(OH)], 168.8 (C-2). IR (KBr): ν = 1697 cm-¹. MS (ES+): m/z (%) = 851.6 (10) [3 M + Na]+, 575.4 (58) [2 M + Na]+, 570.4 (13) [2 M + NH4]+, 299.2 (35) [M + Na]+, 294.2 (100) [M + NH4]+, 277.2 (88) [M + 1]+, 259.2 (73), 145.1 (8). Anal. Calcd (%) for C12H24O5Si: C, 52.14; H, 8.75. Found: C, 52.45; H, 9.18.
25(4 R ,6 S )-4-( tert -Butyldimethylsilyloxy)-6,7-dihydroxy-oxepan-2-one (5) Hydrate 4 (50 mg, 0.18 mmol) was dissolved in MeOH (2 mL) and left to stand at r.t. for 2.5 d. The solvent was evaporated to dryness to give 5 (50 mg, 100%) as a colorless solid. ¹H NMR (300 MHz, CD3OD): δ = 0.14 (s, 6 H, CH3Si), 0.94 (s, 9 H, CH3C), 1.87-2.06 (m, 2 H, H-5), 2.52 (ddd, J = 17.5, 2.9, 2.0 Hz, 1 H, H-3), 2.72 (dd, J = 17.5, 3.8 Hz, 1 H, H-3), 4.42-4.52 (m, 1 H, H-4), 4.56-4.70 (m, 2 H, H-6, H-7). ¹³C NMR (75 MHz, CD3OD): δ = -4.82 (CH3Si), -4.76 (CH3Si), 18.9 (CH3C), 26.2 (CH3C), 30.7 (C-5), 31.0 (C-5), 40.5 (C-3), 64.9 (C-4), 79.0, 79.5, 98.6, 98.8, 172.58 (C-2), 172.60 (C-2). Two sets of ¹³C resonances are observed in the intensity ratio of 1:1. HRMS (ES+): m/z calcd for C12H24O5SiNa+ [M + Na]+: 299.1291; found: 299.1299. Anal. Calcd (%) for C12H24O5Si: C, 52.14; H, 8.75. Found: C, 52.35; H, 8.97.
26(4 R ,6 S )-4-( tert -Butyldimethylsilyloxy)-6-formyltetra-hydro-2 H -pyran-2-one (1) A solution of hydrate 4 (500 mg, 1.81 mmol) in CH2Cl2 (30 mL) was left to stand for 1 d. The solvent was evaporated to afford quantitatively aldehyde 1 as a colorless oil. ¹H NMR (300 MHz, CDCl3): δ = 0.11 (s, 6 H, CH3Si), 0.90 (s, 9 H, CH3C), 1.80-1.91 (m, 1 H, H-5), 2.13 (ddd, J = 14.0, 4.2, 4.2 Hz, 1 H, H-5), 2.55-2.70 (m, 2 H, H-3), 4.37 (m, 1 H, H-4), 5.07 (dd, J = 11.3, 3.9 Hz, 1 H, H-6), 9.83 (s, 1 H, CHO). ¹³C NMR (75 MHz, CDCl3): δ = -4.9 (CH3Si), 17.9 (CCH3), 25.6 (CH3C), 31.4, 39.6, 63.0, 79.2, 167.9 (C-2), 199.3 (CHO). IR (NaCl): ν = 1739, 1697 cm-¹. [α]D ²0 -12.2 (c 1, CHCl3). MS (ES+): m/z (%) = 517.3 (20) [2 M + H]+, 259.1 (100) [M + 1]+, 246.1 (11), 233.1 (15), 221.1 (31), 205.1 (34), 183.1 (9), 169.1 (16), 153.1 (14), 129.1 (33), 127.0(27). HRMS (TOFMS+): m/z calcd for C12H22O4Si+ [M + H]+: 259.1366; found: 259.1366.
27β-Substituted δ-lactone ring is unstable and readily undergoes elimination to unsaturated compounds. For example, see ref. 13, 18.
29
(4
R
,6
S
)-4-(
tert
-Butyldimethylsilyloxy)-6-styryltetra-hydro-2
H
-pyran-2-one
(7)
Benzyltriphenylphosphonium bromide (0.130 g, 3.00
mmol) was dissolved in dry toluene (70 mL) and NaHDMS (5.25 mL,
3.15 mmol, 0.6 M in toluene) was added at r.t. The reaction mixture
was stirred at r.t. for 2.25 h to give ylide 6. Then
the solution of ylide 6 was warmed up to
65 ˚C within 10 min. At this temperature a solution
of pre-dried aldehyde 1 (853 mg, 3.30 mmol)
in toluene (25 mL), prepared from hydrate 4 (913
mg, 3.30 mmol) and toluene, was added. The resulting reaction mixture
was stirred at 65 ˚C for 5 min quenched with EtOH
and allowed to cool down to r.t. The solvent was evaporated, and
the residue was subjected to flash chromatography with ARMEN INSTRUMENT
Spot® apparatus on SiO2 [gradient
elution; EtOAc-hexane (3:97) over 10 min; from 3:97 to
5:95 over 15 min, from 5:95 to 15:85 over 10 min, and from 15:85
to 100:0 over 5 min; flow rate 60 mL/min] to obtain
a mixture of (E)-7/(Z)-7 in the ratio
of 63:37 (740 mg, 74%). For analysis, the isomers were separated
by the second flash chromatography under the same conditions as
described above.
Data for Compound
(
E
)-7
White
solid; mp 57.5 ˚C (DSC onset). ¹H
NMR (400 MHz, CDCl3): δ = 0.00
(s, 6 H, CH3Si), 0.81 (s, 9 H, CH3C), 1.73-1.82
(m, 1 H), 1.87-1.95 (m, 1 H), 2.48-2.61 (m, 2
H), 4.22-4.29 (m, 1 H), 5.21-5.28 (m, 1 H), 6.12
(dd, J = 6.4,
15.9 Hz, 1 H), 6.59 (d, J = 15.9
Hz, 1 H, CHPh), 7.14-7.32 (m, 5 H, Ph). ¹³C
NMR (100 MHz, CDCl3): δ = -5.0
(CH3Si), -4.9 (CH3Si), 17.9, 25.6,
36.9, 39.3, 63.4, 76.1, 126.6, 126.8, 128.1, 128.6, 132.0, 135.9,
169.8. IR (NaCl): ν = 2927, 1727,
1348, 1233, 1165, 1090, 1072, 693 cm-¹.
HRMS (CI+): m/z calcd
for C15H19O3Si+ [M - C4H9]+:
275.1104; found: 275.1110.
Data for
Compound (
Z
)-7
White
solid; mp 65.8 ˚C (DSC onset). ¹H
NMR (400 MHz, CDCl3): δ = 0.05
(s, 6 H, CH3Si), 0.81 (s, 9 H, CH3C), 1.80-2.00
(m, 2 H), 2.52-2.69 (m, 2 H), 4.29-4.35 (m, 1
H), 5.64-5.76 (m, 2 H), 6.67 (d, J = 10.5
Hz, 1 H, CHPh), 7.22-7.36 (m, 5 H, Ph). ¹³C
NMR (100 MHz, CDCl3): δ = -5.1 (CH3Si), -5.0
(CH3Si), 17.8, 25.5, 36.6, 39.2, 63.6, 72.4, 127.6, 128.4,
128.5, 129.0, 133.0, 135.7, 169.8. IR (NaCl): ν = 2927,
1737, 1359, 1239, 1160, 1084, 1065, 697 cm-¹. HRMS
(CI+): m/z calcd
for C15H19O3Si+ [M - C4H9]+: 275.1104;
found: 275.1110.